TIMI Study Group Competitors

Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.

ReSearch Pharmaceutical Services (RPS) merged with PRA in 2013. PRA understands that you want practical solutions that will efficiently and expertly improve your infrastructure to support business needs. Our Strategic Solutions offering provides a broad spectrum of solutions to meet sponsors where they are with their outsourcing needs. As the pioneer of the Embedded SolutionsTM model, we have mastered the art of elegant transformation as sponsors re-align their operating model to more efficiently manage their development portfolio with greater flexibility and control . Our custom-built development solutions empower companies with limited infrastructure to leverage our extensive experience to bring innovative new approaches that enhance quality, streamline development processes and improve efficiency. Our staff augmentation solutions enable sponsors to fill gaps and maintain business continuity seamlessly. For those sponsors desiring an FSP model, we bring years of experience in this method.

As part of the Duke University School of Medicine, the Duke Clinical Research Institute (DCRI) is known globally for conducting groundbreaking multinational trials, managing major national patient registries, and performing landmark research. As an academic clinical research organization, we combine the faculty expertise of practicing physicians with the full-service operational capabilities of a major CRO. We design and implement innovative clinical trials that advance the understanding of health and disease and inform efforts to improve the quality of care. Our experience stretches from phase I to phase IV and beyond, encompassing post-approval analyses and health economics. The breadth of our work in numerous therapeutic areas is matched by the depth of our knowledge, which we disseminate through high-impact publications and global meetings. Since 1996, DCRI's faculty and staff have disseminated over 17,500 peer-reviewed publications and have been cited in over 760,500 scientific articles.